Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage
暂无分享,去创建一个
[1] G. Lip,et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.
[2] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[3] Mario Zuccarello,et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.
[4] H. Diener,et al. Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials , 2007, Stroke.
[5] J. Broderick,et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage , 2007, Neurology.
[6] Silvia G. Priori,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text , 2006 .
[7] Silvia G. Priori,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC , 2006 .
[8] M. Pfeffer,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.
[9] J. Le Heuzey,et al. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. , 2006, American heart journal.
[10] Eric E. Smith,et al. Timing of Fresh Frozen Plasma Administration and Rapid Correction of Coagulopathy in Warfarin-Related Intracerebral Hemorrhage , 2006, Stroke.
[11] T. Steiner,et al. Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy: Current Practices and Unresolved Questions , 2006, Stroke.
[12] M. Woodward,et al. Perindopril-Based Blood Pressure–Lowering Reduces Major Vascular Events in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack , 2005, Stroke.
[13] R. Hart,et al. Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas , 2005, Stroke.
[14] T. Tsoi,et al. The Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Atrial Fibrillation , 2005, Cerebrovascular Diseases.
[15] Palle Petersen,et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. , 2005, JAMA.
[16] Margaret C Fang,et al. Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation , 2004, Annals of Internal Medicine.
[17] P. Koudstaal,et al. Transient Ischemic Attacks in Patients With Atrial Fibrillation: Implications for Secondary Prevention: The European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III Trial , 2004, Stroke.
[18] M. Woodward,et al. Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History: The PROGRESS Trial , 2003, Stroke.
[19] G. Olsson,et al. The statin wars , 2003, The Lancet.
[20] S. Olsson,et al. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial , 2003, The Lancet.
[21] Yuchiao Chang,et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.
[22] B. Psaty,et al. The PROGRESS trial: questions about the effectiveness of angiotensin converting enzyme inhibitors. Perindopril pROtection aGainst REcurrent Stroke Study. , 2002, American journal of hypertension.
[23] A. Schmaier,et al. Use of factor IX complex in warfarin-related intracranial hemorrhage. , 1999, Neurosurgery.
[24] Edward Groth,et al. Facts and hypotheses , 1999, Nature Biotechnology.
[25] W. J. Hamilton,et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.
[26] D. Singer,et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.
[27] R. Hart,et al. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. , 1995, Stroke.
[28] Eaft Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993, The Lancet.
[29] S M Nazarian,et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.
[30] M Gent,et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.
[31] Lippincott Williams Wilkins,et al. Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.
[32] Bernard Rosner,et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.
[33] Palle Petersen,et al. PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.
[34] Z. J. Lipowski. Letter: Psychosomatic medicine. , 1974, Lancet.
[35] S. Mayer,et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. , 2007, Mayo Clinic proceedings.
[36] Anders Odén,et al. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. , 2006, Thrombosis research.
[37] M. Woodward,et al. Perindopril-based blood pressure lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or TIA (130th American Neurological Association) , 2005 .
[38] Leandro Provinciali,et al. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .